Supplementary Information
gastrointestinal (GI) toxicity
CHRONIC PHASE CML
The approved dose of bosutinib in chronic phase CML is 400 mg QD in first-line and 500 mg QD in later-line treatment. However, given that gastrointestinal (GI) toxicity typically occurs early after treatment initiation, physicians often tend to start therapy with lower doses although this has never been tested systematically in prospective trials in the Western world. The The online version contains supplementary material available at 10.1007/s00277-023-05394-0.